Antimicrobial resistance (AMR) is a growing global health crisis, with once-effective antibiotics losing efficacy against infections like salmonellosis, tuberculosis, pneumonia, and gonorrhea. The World Health Organization (WHO) has ranked AMR among the top 10 global health threats and released a priority list of resistant pathogens needing urgent attention.
The 2024 Bacterial Priority Pathogens List (BPPL) includes 15 families of antibiotic-resistant pathogens, categorised as critical, high, or medium priority based on their threat level.
- Critical Priority: Includes Gram-negative bacteria like Acinetobacter baumannii, resistant Enterobacterales, and rifampicin-resistant Mycobacterium tuberculosis—noted for severe infections, gene transfer ability, and high impact in low- and middle-income countries (LMICs).
- High Priority: Includes Salmonella, Shigella, Pseudomonas aeruginosa, Staphylococcus aureus, Neisseria gonorrhoeae, and Enterococcus faecium, due to rising resistance and burden in healthcare and community settings.
- Medium Priority: Covers pathogens like Group A and B Streptococci, Streptococcus pneumoniae, and Haemophilus influenzae, which pose risks in resource-limited areas and among vulnerable populations.
AMR already causes over a million deaths annually and threatens the effectiveness of modern medicine, underscoring the urgent need for new antibiotics and public health measures.
Innovation Without Incentive: The Dilemma in Antibiotic Development
The antibiotics market is caught in a paradox. On one hand, AMR is escalating into a global health crisis; on the other, the economic model underpinning antibiotic development is fundamentally broken.
Antibiotics are typically used for short durations and are often reserved as last-line treatments, making them far less profitable than long-term therapies for chronic diseases. As a result, even when scientific advances—such as AI-assisted drug discovery—yield promising candidates, the path to market success remains steep. Low sales volume, cautious prescribing habits, and the preference for older generics over newer, more expensive drugs have all contributed to an unattractive commercial landscape for developers.
To overcome these challenges, governments and regulatory agencies have introduced a mix of "push" and "pull" incentives. Push incentives, such as early-stage research grants, aim to lower the cost of innovation. Pull incentives, on the other hand, reward successful development outcomes by ensuring a viable market.
In the United States, regulatory tools like the Qualified Infectious Disease Product (QIDP) designation enable companies to fast-track approvals using Phase 2 data, receive priority review (reducing decision times from 10 to 6 months), and gain five additional years of market exclusivity. The UK has implemented a subscription-style payment model that provides fixed annual revenues to antibiotic developers, regardless of sales volume. This de-links profitability from usage, allowing for stewardship without penalizing innovation. The EU is exploring similar strategies, although progress has been gradual.
Still, access remains a major barrier—particularly in low- and middle-income countries (LMICs), where resistance-related deaths are higher than in high-income regions. In response, international efforts are underway to harmonize regulatory pathways and speed up access. The WHO recently designated several national agencies, including the US FDA and the European Medicines Regulatory Network, as WHO-Listed Authorities (WLAs). This enables lower-income countries to rely on established regulatory reviews, lowering costs and reducing delays in accessing new antibiotics.
Together, these push-pull strategies and regulatory harmonization efforts are vital steps toward revitalizing antibiotic development. But to succeed, they must be accompanied by global collaboration, strong stewardship frameworks, and a commitment to equitable access—especially in the countries facing the highest burden of resistance.
What Next-Generation Antibiotics Must Deliver
Looking ahead, innovation must go beyond developing new drugs—it must solve the limitations of traditional antibiotics. Small-molecule antibiotics ...
(All Rights Reserved)